BR112015018317B1 - Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica - Google Patents

Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica Download PDF

Info

Publication number
BR112015018317B1
BR112015018317B1 BR112015018317-4A BR112015018317A BR112015018317B1 BR 112015018317 B1 BR112015018317 B1 BR 112015018317B1 BR 112015018317 A BR112015018317 A BR 112015018317A BR 112015018317 B1 BR112015018317 B1 BR 112015018317B1
Authority
BR
Brazil
Prior art keywords
compound
methyl
mmol
salt
formula
Prior art date
Application number
BR112015018317-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015018317A2 (pt
BR112015018317A8 (pt
Inventor
Christophe Buon
Louis-David Cantin
Yun-Jin Hu
Xuehong Luo
Miroslaw Jerzy Tomaszewski
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of BR112015018317A2 publication Critical patent/BR112015018317A2/pt
Publication of BR112015018317A8 publication Critical patent/BR112015018317A8/pt
Publication of BR112015018317B1 publication Critical patent/BR112015018317B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112015018317-4A 2013-01-31 2014-01-31 Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica BR112015018317B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759123P 2013-01-31 2013-01-31
US61/759,123 2013-01-31
PCT/CA2014/050062 WO2014117274A1 (en) 2013-01-31 2014-01-31 Imidazopyridine compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR112015018317A2 BR112015018317A2 (pt) 2017-07-18
BR112015018317A8 BR112015018317A8 (pt) 2022-08-30
BR112015018317B1 true BR112015018317B1 (pt) 2022-10-04

Family

ID=51261357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018317-4A BR112015018317B1 (pt) 2013-01-31 2014-01-31 Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica

Country Status (17)

Country Link
US (9) US9598409B2 (OSRAM)
EP (3) EP3998267A1 (OSRAM)
JP (1) JP6373280B2 (OSRAM)
KR (1) KR102120513B1 (OSRAM)
CN (2) CN107485612B (OSRAM)
AU (1) AU2014211962B2 (OSRAM)
BR (1) BR112015018317B1 (OSRAM)
CA (1) CA2898665C (OSRAM)
DK (2) DK3381917T3 (OSRAM)
ES (2) ES2674087T3 (OSRAM)
MX (1) MX372934B (OSRAM)
NO (1) NO2910833T3 (OSRAM)
PL (2) PL3381917T3 (OSRAM)
PT (2) PT2951177T (OSRAM)
RU (1) RU2656593C2 (OSRAM)
TR (1) TR201807602T4 (OSRAM)
WO (1) WO2014117274A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117274A1 (en) * 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and uses thereof
CA2969952A1 (en) 2014-12-09 2016-06-16 Adam James Davenport 1,3-thiazol-2-yl substituted benzamides
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CN116854693A (zh) * 2016-09-30 2023-10-10 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
EP3862000B1 (en) 2018-10-05 2023-10-18 Shionogi & Co., Ltd Medicine for treating chronic cough
AU2019358327B2 (en) * 2018-10-10 2025-04-24 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment of pruritus with P2X3 antagonists
ES3033466T3 (en) 2018-11-13 2025-08-04 Glaxosmithkline Intellectual Property No 3 Ltd Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
CN113727716A (zh) * 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CA3184277A1 (en) * 2020-02-14 2021-08-19 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
WO2021161105A1 (en) * 2020-02-14 2021-08-19 Bellus Health Cough Inc. P2x3 modulators
CN113549068B (zh) * 2020-04-24 2022-12-02 上海拓界生物医药科技有限公司 一类新型咪唑并吡啶化合物、其制备方法及其在医药上的应用
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
US20230406850A1 (en) * 2020-06-29 2023-12-21 Wuhan Ll Science And Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
WO2022033567A1 (zh) * 2020-08-13 2022-02-17 上海拓界生物医药科技有限公司 苯并咪唑类衍生物、其制备方法及医药用途
CN112485351A (zh) * 2020-11-18 2021-03-12 天津华津制药有限公司 一种右佐匹克隆光学异构体的检测方法
WO2022117062A1 (zh) * 2020-12-04 2022-06-09 上海拓界生物医药科技有限公司 含有稠合三环的化合物及其医药用途
CN114805237A (zh) * 2021-01-22 2022-07-29 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
CN114805340A (zh) * 2021-01-22 2022-07-29 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
WO2022268218A1 (zh) * 2021-06-24 2022-12-29 武汉朗来科技发展有限公司 一种杂环烷基类化合物的制备方法、其中间体及其应用
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
WO2024194352A1 (en) 2023-03-23 2024-09-26 Glaxosmithkline Intellectual Property (No.3) Limited Deuterated p2x3 modulators
WO2025125445A1 (en) 2023-12-12 2025-06-19 Glaxosmithkline Intellectual Property (No.3) Limited Process of manufacture of p2x3 antagonists including camlipixant
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2025210540A1 (en) 2024-04-02 2025-10-09 Assia Chemical Industries Ltd. Solid state forms of camlipixant and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
BRPI0714315B8 (pt) * 2006-06-29 2021-05-25 Hoffmann La Roche arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US9238647B2 (en) * 2009-03-23 2016-01-19 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
BR112012011518B8 (pt) * 2009-11-18 2023-01-10 Astrazeneca Ab Compostos, composição farmacêutica, kit e usos de um composto
WO2014117274A1 (en) 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and uses thereof

Also Published As

Publication number Publication date
CN107485612A (zh) 2017-12-19
BR112015018317A2 (pt) 2017-07-18
PL3381917T3 (pl) 2021-12-27
KR102120513B1 (ko) 2020-06-08
NO2910833T3 (OSRAM) 2018-04-07
ES2674087T3 (es) 2018-06-27
EP3381917B1 (en) 2021-09-08
DK2951177T3 (en) 2018-06-14
ES2895225T3 (es) 2022-02-18
US20200390779A1 (en) 2020-12-17
CN105246888A (zh) 2016-01-13
CN105246888B (zh) 2017-09-05
US20220062290A1 (en) 2022-03-03
AU2014211962A1 (en) 2015-08-13
US20150361078A1 (en) 2015-12-17
WO2014117274A1 (en) 2014-08-07
CN107485612B (zh) 2021-03-30
EP3381917A1 (en) 2018-10-03
BR112015018317A8 (pt) 2022-08-30
RU2656593C2 (ru) 2018-06-06
EP2951177A1 (en) 2015-12-09
EP2951177B1 (en) 2018-04-04
HK1248138A1 (zh) 2018-10-12
US9814725B2 (en) 2017-11-14
US20210228588A1 (en) 2021-07-29
KR20150123812A (ko) 2015-11-04
TR201807602T4 (tr) 2018-06-21
MX372934B (es) 2020-04-08
EP2951177A4 (en) 2016-06-01
US20190030040A1 (en) 2019-01-31
US9598409B2 (en) 2017-03-21
US20190231789A1 (en) 2019-08-01
DK3381917T3 (da) 2021-10-18
US20180015099A1 (en) 2018-01-18
AU2014211962B2 (en) 2017-11-16
CA2898665C (en) 2021-02-16
PT3381917T (pt) 2021-10-27
CA2898665A1 (en) 2014-08-07
PL2951177T3 (pl) 2018-12-31
EP3998267A1 (en) 2022-05-18
US9937185B2 (en) 2018-04-10
US20200138826A1 (en) 2020-05-07
MX2015009950A (es) 2016-02-05
JP2016506935A (ja) 2016-03-07
PT2951177T (pt) 2018-05-23
JP6373280B2 (ja) 2018-08-15
US20170143730A1 (en) 2017-05-25
RU2015133450A (ru) 2017-03-07

Similar Documents

Publication Publication Date Title
BR112015018317B1 (pt) Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica
ES2442797T3 (es) Compuestos de benzoimidazol y sus utilizaciones
US20230406851A1 (en) Imidazopyridine compounds and uses thereof
HK1248138B (zh) 咪唑并吡啶化合物及其用途

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BELLUS HEALTH COUGH INC. (CA)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/01/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: BELLUS HEALTH INC. (CA)

B25A Requested transfer of rights approved

Owner name: 14245563 CANADA INC. (CA)

B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC (CA)

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED (GB)